Faron Pharmaceuticals Oy (LSE:FARN) Beneish M-Score: 0.00 (As of Jun. 29, 2026)

What is Faron Pharmaceuticals Oy Beneish M-Score?

Faron Pharmaceuticals Oy LSE:FARN -0.24% 22 Beneish M-Score is 0.00 as of Jun. 29, 2026. GuruFocus rates LSE:FARN with a GF Score™ of 22/100. The stock has 4 warning signs investors should review. Among 829 Biotechnology companies, Faron Pharmaceuticals Oy ranks worse than 120627.14% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Faron Pharmaceuticals Oy's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Faron Pharmaceuticals Oy was -2.02. The lowest was -2.02. And the median was -2.02.

Faron Pharmaceuticals Oy Beneish M-Score Related Terms

Faron Pharmaceuticals Oy Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Faron Pharmaceuticals Oy's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Faron Pharmaceuticals Oy Beneish M-Score Chart

Faron Pharmaceuticals Oy Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Beneish M-Score

Get a 7-Day Free Trial

0.00

Faron Pharmaceuticals Oy Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
Beneish M-Score	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

LSE:FARN vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, Faron Pharmaceuticals Oy's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Faron Pharmaceuticals Oy Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Faron Pharmaceuticals Oy's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Faron Pharmaceuticals Oy's Beneish M-Score falls into.

Save Embed

22GF Score

Faron Pharmaceuticals Oy LSE:FARN

Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Faron Pharmaceuticals Oy Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Faron Pharmaceuticals Oy for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 *

0.528 *

0.404 *

0.892 *

0.115 *

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 *

4.679 *

0.327 *

This Year (Dec25) TTM:

Last Year (Dec24) TTM:

Total Receivables was £0.30 Mil.
Revenue was £0.00 Mil.
Gross Profit was £0.00 Mil.
Total Current Assets was £13.84 Mil.
Total Assets was £15.02 Mil.
Property, Plant and Equipment(Net PPE) was £0.17 Mil.
Depreciation, Depletion and Amortization(DDA) was £0.29 Mil.
Selling, General, & Admin. Expense(SGA) was £2.48 Mil.
Total Current Liabilities was £16.51 Mil.
Long-Term Debt & Capital Lease Obligation was £12.49 Mil.
Net Income was £-23.84 Mil.
Gross Profit was £0.00 Mil.
Cash Flow from Operations was £-15.68 Mil.

Total Receivables was £0.17 Mil.
Revenue was £0.00 Mil.
Gross Profit was £0.00 Mil.
Total Current Assets was £9.17 Mil.
Total Assets was £10.37 Mil.
Property, Plant and Equipment(Net PPE) was £0.25 Mil.
Depreciation, Depletion and Amortization(DDA) was £0.26 Mil.
Selling, General, & Admin. Expense(SGA) was £2.67 Mil.
Total Current Liabilities was £8.42 Mil.
Long-Term Debt & Capital Lease Obligation was £6.85 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(0.298 / 0)	/	(0.166 / 0)
	=		/
	=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(0 / 0)	/	(0 / 0)
	=		/
	=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (13.842 + 0.165) / 15.02)	/	(1 - (9.165 + 0.246) / 10.371)
	=	0.067443	/	0.092566
	=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	0	/	0
	=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(0.261 / (0.261 + 0.246))	/	(0.285 / (0.285 + 0.165))
	=	0.514793	/	0.633333
	=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(2.475 / 0)	/	(2.671 / 0)
	=		/
	=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((12.49 + 16.509) / 15.02)	/	((6.853 + 8.424) / 10.371)
	=	1.930692	/	1.47305
	=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(-23.842 - 0	-	-15.675)	/	15.02
	=	-0.543742

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →

What does a Beneish M-Score of 0.00 mean?

Faron Pharmaceuticals Oy (LSE:FARN) has a Beneish M-Score of 0.00 as of Jun. 29, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Faron Pharmaceuticals Oy and its competitors. According to the industry distribution chart, Faron Pharmaceuticals Oy ranks #999999 out of 829 companies in the Biotechnology industry.

Is Faron Pharmaceuticals Oy's Beneish M-Score too high?

Faron Pharmaceuticals Oy's current Beneish M-Score is 0.00. Based on the distribution chart, Faron Pharmaceuticals Oy ranks #999999 out of 829 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Faron Pharmaceuticals Oy has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.

How does Faron Pharmaceuticals Oy's Beneish M-Score compare to VRTX and REGN?

According to the Biotechnology industry distribution chart, Faron Pharmaceuticals Oy ranks #999999 out of 829 companies for Beneish M-Score. This places Faron Pharmaceuticals Oy in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Beneish M-Score for a Biotechnology company?

A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Beneish M-Score mean?

A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Faron Pharmaceuticals Oy and its competitors. Faron Pharmaceuticals Oy's current Beneish M-Score is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Faron Pharmaceuticals Oy stock overvalued right now?

Faron Pharmaceuticals Oy (LSE:FARN) has a current Beneish M-Score of 0.00. The current Beneish M-Score is 0.00. Faron Pharmaceuticals Oy's overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Beneish M-Score calculated?

Beneish M-Score is calculated from a company's financial statements. For Faron Pharmaceuticals Oy (LSE:FARN), the current Beneish M-Score is 0.00 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Faron Pharmaceuticals Oy Business Description

Industry Healthcare Biotechnology

Comparable Companies LSE:4BB LSE:BVXP LSE:HEMO LSE:POLB LSE:COIL LSE:SBTX LSE:SAR LSE:AREC LSE:IMM LSE:APTA VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges FARON:Finland 4FR:Germany

Address Joukahaisenkatu 6 B, Turku, FIN, 20520

Website https://www.faron.com

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company. The company has one operating and reportable segment. The Group has a pipeline based on the receptors involved in the regulation of immune response in oncology, organ damage, and bone marrow regeneration. Faron is a late clinical stage drug discovery and development Group. The company includes Bexmarilimab in its pipeline. Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and improve clinical outcomes by targeting myeloid cell function in the microenvironment and igniting the immune system against cancer.

22GF Score

Get the complete analysis for LSE:FARN

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.41

Price

View LSE:FARN Analysis

See Beneish M-Score data for all stocks →